For most of the past decade, the medicines that transformed weight management have arrived through a needle, and the search for a version that works as an ordinary tablet has defeated a long line of candidates. Orforglipron is the newest answer to that problem, and on 10 August 2026 the UK became the first country in Europe to authorise it. The coverage that followed was enthusiastic and, in places, loose with the detail. This article sets out what was actually authorised, what the evidence shows, and what it does and does not change for anyone considering treatment.
What was authorised, and when
The Medicines and Healthcare products Regulatory Agency authorised orforglipron, which Eli Lilly sell under the brand name Foundayo, on 10 August 2026. The authorisation covers weight loss and weight maintenance in adults with a body mass index of 30 or above, or between 27 and 30 with at least one weight-related health condition, used alongside a reduced-calorie diet and increased physical activity. Separately, it is authorised to improve blood sugar control in adults with type 2 diabetes that is not adequately controlled. Eli Lilly are the same company behind Mounjaro, which is worth knowing because the two medicines are frequently discussed as though they were interchangeable, and they are not.
Orforglipron and Foundayo: why there are two names
Coverage of the approval has used two names more or less interchangeably, which has caused some understandable confusion about whether these are one medicine or two. They are one. Orforglipron is the generic name, the internationally recognised term for the active ingredient itself, and Foundayo is the brand name Eli Lilly have registered for their version of it in the UK. Every medicine carries both. The pattern is exactly the one already familiar from this drug family: tirzepatide is the generic name for the medicine sold as Mounjaro, and semaglutide for the one sold as Wegovy. The generic name tends to dominate scientific papers and regulatory documents, while the brand name is what appears on the box.
The practical consequence is worth knowing if you are reading around the subject. Searching either name will turn up material about the same tablet, and a headline about Foundayo and a trial report about orforglipron are describing identical things. It also matters for safety. Because the brand name is new and unfamiliar, it is precisely the sort of term that unregulated sellers attach to products that have nothing to do with the licensed medicine. Neither name can currently be bought legitimately in the UK, so any site offering either is not supplying a UK-licensed product, whichever word it puts on the page.
Why a tablet was the hard part
GLP-1 medicines mimic a natural gut hormone that curbs appetite and steadies blood sugar. The catch has always been chemistry rather than biology. Semaglutide and tirzepatide are peptides, which are essentially small proteins, and the digestive system treats proteins as food: swallow one and it is largely broken down before it reaches the bloodstream. That is why these medicines were injected, and why the oral semaglutide tablets that do exist need an absorption enhancer plus a strict empty-stomach routine to get enough of the dose through. Orforglipron sidesteps the problem entirely by not being a peptide. It is a small molecule, built to survive digestion the way most conventional tablets do, which is what allows it to be swallowed at any time of day with or without food or water.
What the trials actually showed
Two large phase 3 trials tested it directly. In ATTAIN-1, in adults with obesity or overweight without type 2 diabetes, participants on the highest dose lost an average of around 11% of their body weight over 72 weeks, against roughly 2% for those on placebo. Just over half the treatment group lost at least a tenth of their body weight, compared with around one in eight on placebo, and average waist circumference fell by about 10 cm against roughly 3 cm. ATTAIN-2, which studied adults who also had type 2 diabetes, found an average loss of around 10.5% over the same period. These are meaningful results: a 10% reduction in body weight is the threshold at which blood pressure, blood sugar, joint pain and sleep apnoea reliably improve.
How it compares with what already exists
Here the honest answer is more complicated than the headlines suggested. On average weight loss, orforglipron is the most modest of the current GLP-1 options rather than the most effective. Tirzepatide, the active ingredient in Mounjaro, produced average losses of around 21% at its highest dose over 72 weeks in its main trial, and oral semaglutide, the Wegovy pill, produced around 15% over 68 weeks. Comparing across separate trials always needs caution, because the participants, designs and durations differ, but the ordering is consistent enough to be taken seriously. What orforglipron offers is not greater weight loss. It is a genuinely unrestricted tablet: no injection, no fridge, no empty stomach, no half-hour wait before breakfast. For someone who will not or cannot inject, or whose mornings make the oral semaglutide routine impractical, that convenience may matter more than the difference in the averages. For someone whose priority is the largest likely weight loss, it does not.
Who it is for, and who decides
The authorised criteria mirror those used across weight-management medicines in the UK: a BMI of 30 or above, or 27 to 30 alongside a condition such as type 2 diabetes, high blood pressure, sleep apnoea or raised cholesterol. Meeting them makes someone potentially eligible rather than automatically suitable. Orforglipron is a prescription-only medicine, so a prescriber has to weigh medical history, current medicines, pregnancy plans and previous experience with this drug family before it can be considered, and there will be people who meet the BMI criteria for whom it is the wrong choice.
What happens next
Authorisation is a regulatory decision about safety, quality and effectiveness. It is not a launch date, and the two are routinely confused. Eli Lilly still have to bring the product to the UK market, and separately the National Institute for Health and Care Excellence is appraising whether the NHS should fund it, with guidance expected on 18 November 2026. Private availability is widely expected in late 2026 or early 2027, though no date has been confirmed and previous GLP-1 approvals have taken varying amounts of time to translate into supply. Until then it cannot legally be sold in the UK, and any site offering it should be treated with real suspicion.
If you are already on treatment
Nothing about this authorisation is a reason to change what is working. If you are losing weight steadily on an injection you tolerate, a new tablet with lower average results is not an upgrade, and switching purely because something is new tends to cost momentum. The more interesting question, and one with early evidence behind it, is whether orforglipron might work as a maintenance option for people who have already reached their target on an injectable and would prefer not to keep injecting indefinitely. A trial designed around exactly that scenario found people who switched held onto the weight they had lost. That is promising rather than settled, and it is a conversation for a review appointment once the product is actually available, not a plan to make now.
